3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
58
Squamous Cell Carcinoma of Head and Neck
37
Nasopharyngeal Carcinoma
27
Lung Neoplasms
25
Uterine Cervical Neoplasms
22
Biliary Tract Neoplasms
22
Esophageal Squamous Cell Carcinoma
20
Oropharyngeal Neoplasms
18
Head and Neck Neoplasms
17
Cholangiocarcinoma
17
Urinary Bladder Neoplasms
14
Neoplasms
14
Neoplasm Metastasis
14
Ovarian Neoplasms
13
Esophageal Neoplasms
12
Carcinoma
12
Colorectal Neoplasms
11
Stomach Neoplasms
10
Small Cell Lung Carcinoma
10
Carcinoma, Transitional Cell
8
Mouth Neoplasms
7
Laryngeal Neoplasms
7
Hypopharyngeal Neoplasms
7
Carcinoma, Squamous Cell
7
Recurrence
6
Nasopharyngeal Neoplasms
5
Gallbladder Neoplasms
5
Endometrial Neoplasms
5
Breast Neoplasms
5
Bile Duct Neoplasms
5
Interventions
pembrolizumab
1
enfortumab vedotin
1
Therapeutics
1
Radiation Dose Hypofractionation
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cystectomy
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Urologic Diseases
×
Cisplatin
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled